➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Theobromine

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Theobromine?

Theobromine is an investigational drug.

There have been 4 clinical trials for Theobromine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2015.

The most common disease conditions in clinical trials are Paralysis, Diverticulitis, and Colorectal Neoplasms. The leading clinical trial sponsors are Thomas Steffen, Gottfried und Julia Bangerter-Rhyner Foundation, Switzerland, and Centre hospitalier de l'Université de Montréal (CHUM).

There are two US patents protecting this investigational drug and twenty-six international patents.

Recent Clinical Trials for Theobromine
Does Caffeine Reduce Postoperative Bowel Paralysis After Elective Colectomy?Gottfried und Julia Bangerter-Rhyner Foundation, SwitzerlandN/A
Does Caffeine Reduce Postoperative Bowel Paralysis After Elective Colectomy?Thomas SteffenN/A
Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic SubjectsCanadian Institutes of Health Research (CIHR)Phase 4

See all Theobromine clinical trials

Clinical Trial Summary for Theobromine

Top disease conditions for Theobromine
Top clinical trial sponsors for Theobromine

See all Theobromine clinical trials

US Patents for Theobromine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Theobromine   Start Trial Compounds for the treatment of infectious diseases Hoffmann-La Roche Inc. (Little Falls, NJ)   Start Trial
Theobromine   Start Trial Therapeutic compounds and methods of use thereof GENENTECH, INC. (South San Francisco, CA) XENON PHARMACEUTICALS INC. (Burnaby, BC, CA)   Start Trial
Theobromine   Start Trial Pyrrolidinone derivatives as MetAP-2 inhibitors Merck Patent GmbH (Darmstadt, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.